Literature DB >> 6345588

Defect in cooperativity in insulin receptors from a patient with a congenital form of extreme insulin resistance.

S I Taylor, S Leventhal.   

Abstract

Previously, we have described a novel qualitative defect in insulin receptors from a patient with a genetic form of extreme insulin resistance (leprechaunism). Receptors from this insulin-resistant child are characterized by two abnormalities: (a) an abnormally high binding affinity for insulin, and (b) a markedly reduced sensitivity of 125I-insulin binding to alterations in pH and temperature. In this paper, we have investigated the kinetic mechanism of this abnormality in steady-state binding. The increased binding affinity for 125I-insulin results from a decrease in the dissociation rate of the hormone-receptor complex. In addition, the cooperative interactions among insulin binding sites are defective with insulin receptors from this child with leprechaunism. With insulin receptors on cultured lymphocytes from normal subjects, both negative and positive cooperativity may be observed. Porcine insulin accelerates the dissociation of the hormone-receptor complex (negative cooperativity). In contrast, certain insulin analogs such as desoctapeptide-insulin and desalanine-desasparagine-insulin retard the dissociation of the hormone-receptor complex (positive cooperativity). With insulin receptors from the leprechaun child, positive cooperativity could not be demonstrated, although negative cooperativity appeared to be normal. It seems likely that the same genetic defect may be responsible for the abnormalities in both insulin sensitivity and positive cooperativity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345588      PMCID: PMC370372          DOI: 10.1172/jci110922

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Binding of hormones to receptors. An alternative explanation of nonlinear Scatchard plots.

Authors:  S I Taylor
Journal:  Biochemistry       Date:  1975-06-03       Impact factor: 3.162

2.  Cooperativity in ligand binding: a new graphic analysis.

Authors:  P De Meyts; J Roth
Journal:  Biochem Biophys Res Commun       Date:  1975-10-27       Impact factor: 3.575

3.  Insulin binding to the human lymphocyte receptor. Evaluation of the negative cooperativity model.

Authors:  R J Pollet; M L Standaert; B A Haase
Journal:  J Biol Chem       Date:  1977-08-25       Impact factor: 5.157

4.  Site-site interactions among insulin receptors. Characterization of the negative cooperativity.

Authors:  P DeMeyts; A R Bainco; J Roth
Journal:  J Biol Chem       Date:  1976-04-10       Impact factor: 5.157

5.  Agonist-induced increase in apparent beta-adrenergic receptor size.

Authors:  L E Limbird; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

6.  Further evidence for functional heterogeneity of adipocyte insulin receptors.

Authors:  J M Olefsky; H Chang
Journal:  Endocrinology       Date:  1979-02       Impact factor: 4.736

7.  Negative cooperativity: a positive finding?

Authors:  D Rodbard
Journal:  Am J Physiol       Date:  1979-09

8.  Characterization of antibodies to the insulin receptor: a cause of insulin-resistant diabetes in man.

Authors:  J S Flier; C R Kahn; D B Jarrett; J Roth
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

9.  Insulin resistance due to a defect distal to the insulin receptor: demonstration in a patient with leprechaunism.

Authors:  M Kobayashi; J M Olefsky; J Elders; M E Mako; B D Given; H K Schedwie; R H Fiser; R L Hintz; J A Horner; A H Rubenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

10.  Direct method for detection and characterization of cell surface receptors for insulin by means of 125I-labeled autoantibodies against the insulin receptor.

Authors:  D B Jarrett; J Roth; C R Kahn; J S Flier
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

View more
  8 in total

1.  Negative and positive site-site interactions, and their modulation by pH, insulin analogs, and monoclonal antibodies, are preserved in the purified insulin receptor.

Authors:  C C Wang; I D Goldfine; Y Fujita-Yamaguchi; H G Gattner; D Brandenburg; P De Meyts
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

Review 2.  Transient and permanent neonatal diabetes.

Authors:  S Fösel
Journal:  Eur J Pediatr       Date:  1995-12       Impact factor: 3.183

3.  Analysis of insulin receptors on human lymphoblastoid cell lines by flow cytometry.

Authors:  R Maron; S I Taylor; R Jackson; C R Kahn
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

4.  Tyrosine kinase activity of insulin receptors from an insulin-resistant patient with leprechaunism.

Authors:  A Cama; S I Taylor
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

5.  Insulin receptor degradation is accelerated in cultured lymphocytes from patients with genetic syndromes of extreme insulin resistance.

Authors:  A McElduff; J A Hedo; S I Taylor; J Roth; P Gorden
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

6.  Insulin receptor biosynthesis in cultured lymphocytes from insulin-resistant patients.

Authors:  J A Hedo; V Y Moncada; S I Taylor
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

7.  Founder effect in the Horn of Africa for an insulin receptor mutation that may impair receptor recycling.

Authors:  E Raffan; M A Soos; N Rocha; A Tuthill; A R Thomsen; C S Hyden; J W Gregory; P Hindmarsh; M Dattani; E Cochran; J Al Kaabi; P Gorden; I Barroso; N Morling; S O'Rahilly; R K Semple
Journal:  Diabetologia       Date:  2011-02-12       Impact factor: 10.122

8.  Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway.

Authors:  Mengna Chi; Yan Ye; Xu Dong Zhang; Jiezhong Chen
Journal:  Drug Des Devel Ther       Date:  2014-02-17       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.